Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pixantrone in HER2-negative metastatic breast cancer
NCT01086605Phase 2Completed
- Sponsor
- Cancer and Leukemia Group B
- Start
- May 2010
- Primary completion
- Jan 2012
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of pixantrone in breast cancer, sponsored by Cancer and Leukemia Group B. Started May 2010; status: completed.
02
Drugs
pixantrone
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT01086605.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01086605.